

ABA Section of Antitrust Law - Product Hopping, Product Withdrawal: Monopolization or Not?

MARCH 13, 2015

Two recent cases, *New York v. Actavis PLC* and *In re: Suboxone Antitrust Litigation* address monopolization claims related to “product hopping” – the phenomenon where a branded pharmaceutical company tries to convert patients from a branded drug facing patent expiration to a newer version with different attributes that remain patented. This program will bring together leading litigators from both sides of these issues to discuss when product hopping raises antitrust issues and how courts should address them.

WilmerHale Partner Mark Ford is a panelist at this event.

READ MORE ABOUT THE EVENT

Speakers



Mark A. Ford

PARTNER

✉ mark.ford@wilmerhale.com

📍 BOSTON

☎ + 1 617 526 6423

Related Solutions

Antitrust and Competition


You May Be Interested In



41st Annual Representing and Managing Tax-Exempt Organizations Conference

APRIL 18–19, 2024

SPEAKING ENGAGEMENT



Cybersecurity and Privacy Protection Conference 2024

APRIL 18–19, 2024

SPEAKING ENGAGEMENT





Managing Cyber Risks in 2024: Regulatory Compliance, Litigation Risk, Third-Party Cybersecurity Incident Exposure

APRIL 24, 2024

SPEAKING ENGAGEMENT

[VIEW ALL EVENTS](#)